Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials

Movement Disorders

Volumn 32, Issue 3, 2017, Pages 319-324

  Espay, Alberto J ^a   Schwarzschild, Michael A ^b   Tanner, Caroline M ^c   Fernandez, Hubert H ^d   Simon, David K ^e   Leverenz, James B ^d   Merola, Aristide ^a   Chen Plotkin, Alice ^f   Brundin, Patrik ^g   Kauffman, Marcelo A ^h   Erro, Roberto ^i,j   Kieburtz, Karl ^k   Woo, Daniel ^l   Macklin, Eric A ^b   Standaert, David G ^m   Lang, Anthony E ^n,o  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g VAN ANDEL RESEARCH INSTITUTE   (United States)

^h HOSPITAL RAMOS MEJÍA   (Argentina)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF VERONA   (Italy)

^k UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^l UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ TORONTO WESTERN HOSPITAL   (Canada)

^o UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

biomarkers; neuroprotection; Parkinson's disease; systems biology

Indexed keywords

BIOLOGICAL MARKER;

AGING; CANCER RESEARCH; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); HUMAN; NERVE CELL DEGENERATION; NEUROPROTECTION; ONCOLOGY; PARKINSON DISEASE; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYSTEMS BIOLOGY; CLASSIFICATION;

BIOMARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; PARKINSON DISEASE;

EID: 85013757375     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26913     Document Type: Review

References (26)

1. Espay AJ, Brundin P, Lang AE. Precision medicine for disease modification in Parkinson disease. Nat Rev Neurol 2017 (in press).
2. Athauda D, Foltynie T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol 2015;11:25–40.
3. Park A, Stacy M. Disease-modifying drugs in Parkinson's disease. Drugs 2015;75:2065–2071.
4. Calne DB, Mizuno Y. The neuromythology of Parkinson's disease. Parkinsonism Relat Disord 2004;10:319–322.
5. Halsted WS. I. A clinical and histological study of certain adenocarcinomata of the breast: and a brief consideration of the supraclavicular operation and of the results of operations for cancer of the breast from 1889 to 1898 at the Johns Hopkins Hospital. Ann Surg 1898;28:557–576.
6. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6–11.
7. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227–1232.
8. Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther 2010;10:955–960.
9. Mendes D, Alves C, Afonso N, et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer—a systematic review. Breast Cancer Res 2015;17:140.
10. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674–690.
11. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591–1601
12. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629–635.
13. Kang JH, Mollenhauer B, Coffey CS, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative Study. Acta Neuropathol 2016;131:935–949.
14. Mollenhauer B, Zimmermann J, Sixel-Doring F, et al.; DeNoPa Study Group. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 2016;87:168–177.
15. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014;71:499–504.
16. Zhu K, van Hilten JJ, Marinus J. Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG. Parkinsonism Relat Disord 2014;20:980–985.
17. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–2170.
18. Terrelonge M, Jr., Marder KS, Weintraub D, Alcalay RN. Csf beta-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci 2016;58:88–92.
19. McMillan CT, Wolk DA. Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease. J Neurol Neurosurg Psychiatry 2016;87:1112–1122.
20. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the Movement Disorder Society Unified Parkinson's Disease Rating Scale: comparison with the Unified Parkinson's Disease Rating Scale. Mov Disord 2013;28:668–670.
21. Simuni T, Caspell-Garcia C, Coffey C, et al.; PPMI Investigators. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort? Parkinsonism Relat Disord 2016;28:62–67.
22. Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 2014;23:6139–6146.
23. West AB. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord 2015;30:180–189.
24. Alcalay RN, Levy OA, Waters CC, et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 2015;138:2648–2658
25. Postuma RB, Gagnon JF, Bertrand JA, Genier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015;84:1104–1113.
26. Parkinson Study Group SURE-PD Investigators,, Schwarzschild MA, Ascherio A, et al. Inosine to increase serum and cerebrospinal fluid urate in Pparkinson disease: a randomized clinical trial. JAMA Neurol 2014;71:141–150.